Teva Pharmaceuticals Sets Ambitious Revenue Target for New Drugs by 2030

Teva Pharmaceuticals unveiled a new business plan on Wednesday, aiming for annual revenues of $6 to $7 billion from innovative drugs by 2030. This strategic shift seeks to significantly increase the proportion of original drugs in the company's portfolio, moving away from its historical reliance on the generic drug market. The new target is part of the strategy led by CEO Richard Francis since 2023, during which Teva's revenues from innovative drugs have more than doubled and now account for over a fifth of its turnover. Key existing innovative drugs include AUSTEDO for movement disorders, AJOVY for migraine prevention, and UZEDY for schizophrenia treatment.

The plan includes a goal to launch at least one new innovative drug annually until 2030. To achieve this, Teva is advancing several treatments through various stages of clinical trials. A notable development is an experimental treatment for celiac disease, which targets the IL-15 protein and has met its primary endpoint in a Phase 2a clinical trial. While this represents significant progress, it does not guarantee market approval. Teva plans to expand clinical testing in the second half of 2027. Additionally, the company is progressing an experimental treatment for vitiligo, a skin condition causing pigment loss, towards later-stage trials. The same therapeutic mechanism is also being explored for other conditions, including certain types of hair loss. Research efforts also encompass new treatments for oncology, asthma, and inflammatory bowel diseases, though some are in early stages and may take years to reach commercialization.

Beyond expanding its drug pipeline, Teva aims for a gross profit margin exceeding 75% in its innovative drug segment by 2030, anticipating that increased sales of these higher-margin products will boost overall profitability. The company projects its total revenues to grow at a mid-single-digit annual rate between 2026 and 2030, with a target of generating over $3.5 billion in annual free cash flow by the end of the decade.

Teva estimates that drugs in advanced development stages could collectively achieve peak annual sales exceeding $10 billion. However, this figure represents a theoretical potential and does not account for the risks of trial failures or regulatory approval challenges.